About Enterprise Therapeutics
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is backed by Epidarex Capital and Imperial Innovations and based in the UK with offices in Cambridge and at the University of Sussex.
In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. Enterprise Therapeutics' scientific strategy is aimed at discovering new disease modifying therapies that target the underlying mechanisms of mucus congestion, which will reduce the frequency of lung infections and improve patient quality of life.
These novel muco-regulatory therapies are being achieved through targeting TMEM16A and ENaC to increase the hydration and clearance of mucus. Enterprise has also identified novel targets and compounds that reduce mucus production, an approach that compliments mucus hydration therapies.
Its management team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. The company benefits from a close working relationship with the School of Life Sciences at the University of Sussex.
About Cystic Fibrosis (CF)
CF is the most common lethal genetic disease of Caucasians with an estimated 100,000 patients worldwide. The average life expectancy, although improving, is approximately 40 years.
About Chronic Obstructive Pulmonary Disease (COPD)
COPD is a chronic disease characterised by a progressive and irreversible decrease in lung function. Globally, COPD is reported to affect over 300 million people and in 2012 was the world’s third highest killer. The estimated economic cost of COPD is >$2 trillion.
About Severe Asthma
Patients with severe asthma are either refractory or poorly managed by current therapies (bronchodilators, steroids). Severe asthma patients comprise around 5% of the estimated 300 million global asthma patients.